Winch Advisory Services’s Iovance Biotherapeutics IOVA Stock Holding History

Winch Advisory Services’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-172	Closed	-$1K	–	261
2015 Q4	$1K	Hold	172	–	–	﹤0.01%	239
2015 Q3	$1K	Hold	172	–	–	﹤0.01%	221
2015 Q2	$2K	Hold	172	–	–	﹤0.01%	253
2015 Q1	$2K	Buy	+172	New	+$1.94K	﹤0.01%	277

Other funds holding IOVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Winch Advisory Services's IOVA Position: Q1 2016 in Review

Winch Advisory Services sold out of Iovance Biotherapeutics (IOVA) in Q1 2016, closing a stake of 172 shares — an estimated $1K sold.

Winch Advisory Services first reported a position in IOVA in Q1 2015 and held it in 4 quarters. The position peaked at $2K in Q2 2015. 77 funds tracked by Wall St. Rank hold IOVA as of Q1 2016.

Winch Advisory Services reported no remaining Iovance Biotherapeutics position as of Q1 2016 after selling out during the quarter.
Winch Advisory Services sold 172 Iovance Biotherapeutics shares in Q1 2016, an estimated $1K.
Winch Advisory Services first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 4 quarters.
Winch Advisory Services's Iovance Biotherapeutics position peaked at $2K in Q2 2015.
77 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2016.

Based on Winch Advisory Services's 13F filing for Q1 2016, filed 12 May 2016.